Argenx Se (ARGX) EBIT Growth (3y) (2019 - 2026)
Powered by 
Analysis
Argenx Se (ARGX) EBIT Growth (3y) (2019 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 6.70% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 8.36% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 89.72% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 24.14% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 44.54% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 44.34% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -18.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 81.27% |
| 10 | Incyte | 25.44 Bn | 20.91 Bn | 1.57 Bn | 53.28% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 89.72% |
| Mar 31, 2026 | 79.65% |
| Dec 31, 2025 | 73.39% |
| Sep 30, 2025 | 54.10% |
| Jun 30, 2025 | 33.15% |
| Mar 31, 2025 | 37.93% |
| Dec 31, 2024 | 34.74% |
| Sep 30, 2024 | 25.92% |
| Jun 30, 2024 | -28.91% |
| Mar 31, 2024 | -1,829.75% |
| Dec 31, 2023 | -29.29% |
| Sep 30, 2023 | 12.11% |
| Jun 30, 2023 | 32.24% |
| Mar 31, 2023 | -43.80% |
| Dec 31, 2022 | -11.19% |
| Sep 30, 2022 | -56.53% |
| Jun 30, 2022 | 52.77% |
| Mar 31, 2022 | -218.92% |
| Dec 31, 2021 | -80.20% |
| Sep 30, 2021 | 31.60% |